Literature DB >> 15293347

Enhanced gene transfer and cell death following p53 gene transfer using photochemical internalisation of glucosylated PEI-DNA complexes.

Alioune Ndoye1, Jean-Louis Merlin, Agnès Leroux, Gilles Dolivet, Patrick Erbacher, Jean-Paul Behr, Kristian Berg, François Guillemin.   

Abstract

BACKGROUND: p53 is frequently mutated in many cancers including human head and neck squamous cell carcinoma and pancreatic cancer. In tumor models, wild-type (wt) p53 gene transfer induces apoptosis and tumor regression in vivo, justifying the extensive clinical investigation of p53 gene therapy.
METHODS: p53 nonviral-mediated gene transfer was achieved using glucosylated polyethylenimine (PEI) in conjunction with photochemical internalisation (PCI). Experimental conditions were optimised using the green fluorescent protein (GFP) as a reporter. p53 gene transfer was then evaluated using semi-quantitative RT-PCR in p53-deleted PANC3 and p53-mutated FaDu cell lines. Following gene transfer, induction of apoptosis was investigated using phosphatidylserine externalisation and nuclear fragmentation assays. Induction of long-term cell death was analysed using colony-forming assays.
RESULTS: PCI was found to enhance GFP gene transfer after 48 h in both cell lines. Whether using glucosylated-PEI alone or associated with PCI, p53 gene transfer was achieved with subsequent recovery of p53 mRNA expression in PANC3 cells and a significant 4-fold increase in p53 mRNA expression in FaDu cells. PCI was found to further enhance p53 mRNA expression by 2.3-fold in PANC3 cells. Spontaneous induction of apoptosis following wt-p53 gene transfer was achieved in both cell lines. PCI was found to enhance apoptosis up to levels similar to those achieved with chemotherapy. As a consequence, long-term cell death was significantly enhanced after wt-p53 gene transfer when PCI was used in both cell lines, yielding up to 60% cell death.
CONCLUSIONS: PCI increases glucosylated-PEI-mediated p53 gene transfer, apoptosis as well as cell death in mutant p53 human cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293347     DOI: 10.1002/jgm.573

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  6 in total

Review 1.  Cell and tissue targeting of nucleic acids for cancer gene therapy.

Authors:  Verena Russ; Ernst Wagner
Journal:  Pharm Res       Date:  2007-03-27       Impact factor: 4.580

2.  Wilms' tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck.

Authors:  Xingru Li; Sofia Ottosson; Sihan Wang; Emma Jernberg; Linda Boldrup; Xiaolian Gu; Karin Nylander; Aihong Li
Journal:  BMC Cancer       Date:  2015-05-01       Impact factor: 4.430

3.  Thyroid transcription factor 1 represses the expression of Ki-67 and induces apoptosis in non-small cell lung cancer.

Authors:  Yun-Fen Zu; Xi-Cai Wang; Yan Chen; Ji-Ying Wang; Xin Liu; Xin Li; Cheng-Wen Li; Yu-Cheng Xie; Yan Luo; Xie-Qin Shang; Jing Guo
Journal:  Oncol Rep       Date:  2012-08-31       Impact factor: 3.906

4.  Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells.

Authors:  D K Adigbli; D G G Wilson; N Farooqui; E Sousi; P Risley; I Taylor; A J Macrobert; M Loizidou
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

5.  Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade.

Authors:  Chia-Sheng Yen; Jung-Chien Chen; Yi-Fang Chang; Ya-Fen Hsu; Pei-Ting Chiu; Ching Shiue; Yu-Fan Chuang; George Ou; Ming-Jen Hsu
Journal:  Sci Rep       Date:  2016-04-28       Impact factor: 4.379

6.  A Novel Hydroxamate-Based Compound WMJ-J-09 Causes Head and Neck Squamous Cell Carcinoma Cell Death via LKB1-AMPK-p38MAPK-p63-Survivin Cascade.

Authors:  Chia-Sheng Yen; Cheuk-Sing Choy; Wei-Jan Huang; Shiu-Wen Huang; Pin-Ye Lai; Meng-Chieh Yu; Ching Shiue; Ya-Fen Hsu; Ming-Jen Hsu
Journal:  Front Pharmacol       Date:  2018-03-01       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.